GlassScriptPhysician profile
Gisa A Schunn
NPI 1144283557
$7,893.66
in general payments reported to CMS, 2019-2025
67 companies · $3,360 in 2025
The $3,360 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.59 · 2020: $68.85 · 2021: $289 · 2022: $627 · 2023: $1,301 · 2024: $2,224 · 2025: $3,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,567 · Education: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,567.43 |
| Education | $317.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $874.26 | 2020-2025 | Tagrisso, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $748.78 | 2021-2025 | |
| Pfizer INC. | $562.60 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $334.35 | 2022-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $323.55 | 2022-2025 | Erleada, Darzalex, Imbruvica |
| Astellas Pharma US INC | $284.42 | 2022-2025 | Padcev, Xospata |
| Genentech USA, INC. | $282.96 | 2022-2025 | Tecentriq, Polivy, Lunsumio |
| Merck Sharp & Dohme LLC | $261.83 | 2022-2025 | Keytruda, Welireg, Reblozyl |
| Incyte Corporation | $246.27 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $242.75 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Ipsen Biopharmaceuticals, INC | $186.89 | 2022-2025 | Onivyde, Tazverik |
| Lilly USA, LLC | $185.25 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $181.86 | 2020-2025 | |
| Celgene Corporation | $175.39 | 2020-2024 | Reblozyl, Opdualag, Pomalyst |
| Eisai INC. | $168.52 | 2022-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $163.60 | 2022-2025 | Enhertu, Injectafer |
| Jazz Pharmaceuticals INC. | $129.26 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $127.17 | 2024-2025 | Libtayo, Lynozyfic |
| Puma Biotechnology, INC. | $121.58 | 2022-2025 | |
| Glaxosmithkline, LLC. | $109.13 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $108.03 | 2024-2025 | |
| Beone Medicines USA, INC. | $104.46 | 2025 | Tevimbra, Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $101.46 | 2023-2025 | |
| Gilead Sciences, INC. | $101.32 | 2021-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $95.82 | 2022-2025 | Xpovio |
| Beigene USA, INC. | $87.28 | 2023-2024 | Brukinsa |
| Tersera Therapeutics LLC | $79.67 | 2025 | Zoladex, Xermelo |
| Emd Serono, INC. | $77.41 | 2023-2025 | Bavencio |
| Taiho Oncology, INC. | $76.55 | 2022-2025 | |
| Sobi, INC | $64.65 | 2023-2025 | |
| Adc Therapeutics America, INC. | $63.74 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $61.14 | 2024-2025 | Clonoseq |
| Geron Corporation | $59.89 | 2024-2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $59.25 | 2023-2025 | Qinlock, Romvimza |
| Caris Mpi, INC. | $58.86 | 2025 | Mi Cancer Seek |
| Genmab U.S., INC. | $57.43 | 2025 | Epkinly |
| Array Biopharma INC | $56.81 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Coherus Oncology, INC. | $53.21 | 2024-2025 | Loqtorzi |
| Pharmacyclics LLC, An Abbvie Company | $52.50 | 2019-2023 | Imbruvica |
| Immunocore Limited | $50.58 | 2025 | Kimmtrak |
| Novocure INC. | $48.38 | 2025 | Optune Gio, Optune Lua (Novottf-200t) |
| Servier Pharmaceuticals LLC | $47.99 | 2024-2025 | |
| Seagen INC. | $45.60 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $42.79 | 2025 | Danziten, Vivimusta |
| Agios Pharmaceuticals, INC. | $37.19 | 2025 | Pyrukynd |
| Accord Healthcare, INC. | $34.70 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.14 | 2024-2025 | Gilotrif |
| Kite Pharma, INC. | $33.03 | 2023-2025 | Yescarta |
| Apellis Pharmaceuticals, INC. | $31.56 | 2024 | Empaveli |
| Sumitomo Pharma America, INC. | $29.22 | 2023-2024 | Orgovyx |
| Stemline Therapeutics INC. | $28.41 | 2025 | Orserdu |
| Alnylam Pharmaceuticals INC. | $25.06 | 2023 | Givlaari |
| Alexion Pharmaceuticals, INC. | $23.83 | 2024 | Ultomiris |
| Kyowa Kirin, INC. | $22.97 | 2025 | |
| Pharmaessentia USA Corporation | $22.25 | 2024 | Besremi |
| Heron Therapeutics, INC. | $21.61 | 2023 | Cinvanti |
| Pharmacosmos Therapeutics INC. | $20.87 | 2025 | Monoferric |
| Cycle Pharmaceuticals INC | $18.91 | 2025 | Phyrago |
| G1 Therapeutics, INC. | $18.80 | 2023 | Cosela |
| Aveo Pharmaceuticals, INC. | $18.00 | 2025 | |
| Exelixis INC. | $17.32 | 2023 | Cabometyx |
| Foundation Medicine, INC. | $17.18 | 2020 | |
| Acrotech Biopharma INC. | $17.12 | 2024 | Beleodaq |
| Janssen Pharmaceuticals, INC | $16.43 | 2023 | Xarelto |
| Blueprint Medicines Corporation | $16.34 | 2025 | Ayvakit |
| Syndax Pharmaceuticals, INC. | $14.45 | 2025 | |
| Rigel Pharmaceuticals, INC. | $9.03 | 2024 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gisa Schunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.